Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room - Key Rheumatology Data

INFORMATION REGLEMENTEE


[06/11/2020 | 14:07]
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6entZ3Q56PHZbJ0db6f0cQDe6eSZitYE4uZ4m3CTukWRf2PFBuJHW8YS=
ot2aEIJUJaQBzZIqv3KsTIDr71wAzWcf79ee_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7Ki=
DwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZ=
xSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa=
2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgTOjhtna4LxBpNyqEzjDLdsAffeI67uZAYfW8=
sOde-2Fz4prPh33K5ho2siUG5TVLQWZu1S9-2FGnYyBTAxXH3n279yCu7LmRC0dwu3GYT80eiAK=
QtDno3dnJbUMJrfWEgPlmLSrXHr5YoQCVfG7uZ6YQQY-3D

** UCB Showcases Key Rheumatology Data at American College of Rheumatology =
Convergence 2020
------------------------------------------------------------

=C2=B7 C-VIEW study results show CIMZIA^=C2=AE (certolizumab pegol) provide=
d reductions in acute anterior uveitis (AAU) flares in patients with axial =
spondyloarthritis (axSpA)
=C2=B7 C-axSpAnd study shows clinically relevant responses in nr-axSpA pati=
ents with either MRI and/or CRP positivity at study baseline
=C2=B7 Long-term findings from Phase 2b studies on UCB=E2=80=99s investigat=
ional IL-17A and IL-17F inhibitor, bimekizumab, demonstrateconsistent durab=
ility of clinical responses in patients with ankylosing spondylitis (AS) an=
d psoriatic arthritis (PsA)

Brussels, Belgium =E2=80=93 November 5, 2020 =E2=80=93 UCB, a global biopha=
rmaceutical company, today announced new data on its TNF inhibitor, CIMZIA^=
=C2=AE (certolizumab pegol), and investigational IL-17A and IL-17F inhibito=
r, bimekizumab. Data are being presented at the American College of Rheumat=
ology (ACR) Convergence 2020 virtual congress on November 5-9, 2020.

=E2=80=9CThe important data we are sharing at ACR Convergence 2020 further =
highlight UCB=E2=80=99s impressive rheumatology research and our unwavering=
commitment to addressing the unmet needs of patients living with rheumatic=
diseases. The data demonstrate the real-world difference that CIMZIA can m=
ake for axSpA and PsA patients by providing major improvements in disease a=
ctivity. Our bimekizumab data further support the selective inhibition of I=
L-17F in addition to IL-17A in AS and PsA, showing that bimekizumab has the=
potential to provide durable clinical responses impacting overall quality =
of life,=E2=80=9D said Emmanuel Caeymaex, Executive Vice President Immunolo=
gy Solutions and Head of US, UCB.

UCB is sharing two-year data from the Phase 4 C-VIEW study addressing a sig=
nificant unmet need for axSpA patients with a history of acute anterior uve=
itis (AAU). AAU is the most common extra-articular manifestation in axSpA, =
affecting up to 40 percent of patients and causing significant pain and ris=
k of irreversible visual impairment.^[i] (https://u7061146.ct.sendgrid.net/=
ls/click?upn=3DvgPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHl=
OgqDj8Vbc5rd23Nd5xqiCbohR6wrmhAt8M2KhMa7A5hYossEA-3DYyC0_xDPID0vOuylFAU8fv4=
e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCO=
G9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M=
-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgSxg9ZYjLpWzyn8Hm=
wn7uYzhFBgaglVJQGVNMQuWNnaFQd4O4tngmzPDkxSoWLgMaYRQLIJHoZ7DLBRYMCaqef-2Bd12=
3zqA9UgwgU4mB-2FvdKft9UcJigdyd-2FsBP2JJyc7dFEhYcvI94XwKSLvV7Sa4iE-3D
The C-VIEW open-label study investigated the impact of CIMZIA treatment on =
AAU flares in patients with axSpA and a recent history of AAU over a two-ye=
ar period.[i] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth=
4pR0LkVwhBuKmBeHsG4Y8GTgp2Ia1I8QM-3DKGH4_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW=
u7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9=
g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-=
2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgckMO2TGcJgQaXdw5cbOLgPrZkO-2F1Cf=
bMqH17ol88pPwcgysmrP-2BvashjR9AetqEKRTmoUQ-2BEHLRlyZlEN5MrLqsS9egw-2FI30FvM=
HMh-2BBl88369XcrgEbt1vKd9lIeJBubtTkH4WhglCwsc3MQowZjY-3D The primary effica=
cy variable was the incidence of AAU flares rate during 96 weeks of CIMZIA =
treatment versus pre-baseline period.^[i] (https://u7061146.ct.sendgrid.net=
/ls/click?upn=3DvgPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJH=
lOgqDj8Vbc5rd23Nd5xqiCbohR6wrmhAt8M2KhMa7A5hYossEA-3DgfCM_xDPID0vOuylFAU8fv=
4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoC=
OG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7=
M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgVDUwgK4b-2F1YiD=
H9mp8wSWkUhT8U2NyvxB-2Fk0YD3l1joCtXssisVSgfoYQbaoU994jhYOhQGwuSo3of277cZlU9=
t7KPzWGwS6hMKFGrkwoMOEwTC4VICWt-2BDnTUK86ndtDgqmaJJ3Kwb6ubE9LcKrno-3D =C2=
=A0Findings revealed an 82 percent reduction in the incidence of AAU flares=
during CIMZIA treatment compared to pre-baseline (rate ratio [95 percent C=
I]: 0.18 [0.12, 0.28], p< 0.001).^[i] (https://u7061146.ct.sendgrid.net/ls/=
click?upn=3DvgPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgq=
Dj8Vbc5rd23Nd5xqiCbohR6wrmhAt8M2KhMa7A5hYossEA-3DmDhS_xDPID0vOuylFAU8fv4e60=
wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9e=
kocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B=
-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1Lgf-2FKeFq31f47o5unkC=
eRvf60A-2FZLfh5NJHAVM9BXGX8AAqtvEkTpNXNHQ9X2CHOAFXCmlL0Fbael1-2FTqOykU3Ne97=
40EnIxV8SWDozCeHxAaCyY2QTUbAQaHePZ32xXpS0fvWwrzALwcCf8014Y5wz8-3D Improveme=
nts in axSpA signs and symptoms were observed by week 96 with 75.6 percent =
of patients achieving Assessment of SpondyloArthritis international Society=
20 (ASAS20) and 58.5 percent achieving ASAS40 responses.^[i] (https://u706=
1146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV=
3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wrmhAt8M2KhMa7A5hYossEA-3Dgd=
D3_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW=
-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2Bd=
QkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2=
uc1LgR8R6eJV6WGx0qWoRb51HwW4LSVR17Oud7mUs3t7XlNGbTX-2FEk6e9UvW2-2FvOk7zTjxf=
2ltD-2B8VNWYSK4EYtlr49uHU4wSy-2F-2BTyk6DhnTCWE5OJRMsVuvw7nv6EoV5tW2rliqZLgH=
-2FHf7IW5pdLEmlqg-3D =C2=A0No new safety signals were identified, compared =
to previous reports.^[i] (https://u7061146.ct.sendgrid.net/ls/click?upn=3Dv=
gPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd=
5xqiCbohR6wrmhAt8M2KhMa7A5hYossEA-3DJaa1_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW=
u7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9=
g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-=
2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1Lgdr4ApDcMn2sqAuUU-2B5BFMcL-2FU-2F=
8VXc5UgWqc-2Fqw5GrcQl2IvPoQL3dphzTb3gNZFet7FOCnrxh-2BZ1MOg43DN5sQjFuhgBiLh0=
jbkfR9L4sWyCTzSnRe2UeCEuEh6LD4u8wX4itHPwCii4wVYFI8UNg-3D

Additionally, UCB is presenting findings from a post hoc analysis of Phase =
3 C-axSpAnd study evaluating CIMZIA treatment in patients with non-radiogra=
phic axial spondyloarthritis (nr-axSpA).^[ii] (https://u7061146.ct.sendgrid=
.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuBLQehfFfo8o6Dk01cZaI50-3DCqjm_xD=
PID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZ=
lGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyi=
mWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1Lg=
XOxppa9jwREmsMcyfhc2tsrhDc2zT-2BfAo6iq1jWz5I7bFO5nByFyK6uAt4YUBdcgoDDKmLl4Q=
CsvM4eCkw-2Fq9U-2FS7yyc0Ar8kGTeX112uU-2FF-2FtrMDsXSmy0dGLDRIZLXhmJzToT9UEIj=
QmZEHcHLwo-3D The study identified that patients with nr-axSpA and either e=
vidence at baseline of sacroiliitis on MRI [MRI+] and/or C-reactive protein=
at least 10mg/ml [CRP+] have clinically relevant responses when treated wi=
th CIMZIA over a 52-week period. Relevant responses were measured by percen=
tage of patients achieving major improvement in ASDAS (ASDAS-MI) and ASAS40=
.^[ii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkV=
whBuBLQehfFfo8o6Dk01cZaI50-3DPScH_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwj=
I3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSs=
FWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9=
SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgYBD3ZBZUuiOgEJSC0e2Kb0GzUf5W-2BlF5VUMmR=
ompnlfNQIVrAEfcn9mxevITIJJiMHh0tpOpzflNqCqKUbAx3q9ePkwg7rG-2BfLW56xnxZdDen9=
841HmwNpwiUPsA5crbguvDbSJ-2BK8Hc2Jk95XeN6k-3D Across all three subgroups (M=
RI+/CRP+, MRI-/CRP+, and MRI+/CRP-), response rates were higher compared to=
placebo for both ASDAS-MI and ASAS40 at Week 12 and Week 52.^[ii] (https:/=
/u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuBLQehfFfo8o=
6Dk01cZaI50-3DZRFF_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bS=
l0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rtt=
kKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4=
U80FXANGvQDfUDq2uc1LgY1-2Bj7qclYXmBxj3xQu9-2B9-2BSozc8754HnuBAY2mfhCxqBmpTa=
0oVh8h6lFUtUShjG2Xv-2BS9JtYYJTqS30UlArwncZV0X9HGmP8DPx2yHpoFy0jNrLcUMhHD5P6=
lX93GOG8Lu4hFguPQaHAetw43iV8k-3D

Data presentations from two Phase 2b studies on UCB=E2=80=99s investigation=
al IL-17A and IL-17F inhibitor, bimekizumab, highlight rapid clinical impro=
vements in joint and skin outcomes; as well as quality of life measures (Qo=
L) in PsA; and long-term tolerability and consistently durable clinical res=
ponses in AS and PsA patients treated with bimekizumab.
=C2=B7 The BE AGILE open-label extension (OLE) study investigated long-term=
efficacy and safety of bimekizumab treatment in patients with AS over a to=
tal treatment duration of 2-years exposure. All patients who entered the OL=
E trial either continued on 160mg bimekizumab every four weeks (Q4W) or dos=
ed down from 320mg Q4W to 160mg Q4W.^[iii] (https://u7061146.ct.sendgrid.ne=
t/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuFBcNiBA2efNfLIHxSZVXCM-3DTVSS_xDPID=
0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB=
52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWU=
Fqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgWV5=
fMv2dAyAtfpX8zWOG9NsHO8H57WLJZnLlk0mV55-2FMVOVNiDxLwbpRcNS9ZdwPeACbMm-2BJXL=
94gnUMmrcqQ8KgCUKVErSdgBdKts4HvysWiR0RkXNylQUPrGeB59uIZKPK7ONBlwnJivjhjtGl6=
U-3D Rapid and sustained improvements in all efficacy outcomes observed in =
patients treated with bimekizumab in the BE AGILE study during weeks 0-48, =
were maintained during the OLE from week 48=E2=80=9396 using non-responder =
imputation methodology.^[iii] (https://u7061146.ct.sendgrid.net/ls/click?up=
n=3DoAq-2FBqldth4pR0LkVwhBuFBcNiBA2efNfLIHxSZVXCM-3DZLlg_xDPID0vOuylFAU8fv4=
e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCO=
G9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M=
-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgWzK8hVwXZDvH3aii=
EeWyoe4ZgAQG7uknMWmSLL-2FVWBExlIUmim7lDnLyz5-2B5qbqU3kbkevDNTqDamzSIEWxvJ-2=
BtzSRQyLCtRrk4uHcgV-2BFyRVaTwoJA84iyQ8uCOdvRO-2FzAHzP3cHsLAdZnBNOr1AI-3D Fu=
rthermore, dose reduction at week 48 from 320 mg Q4W to 160 mg Q4W was not =
followed by loss of response to week 96 and there were no unexpected safety=
findings versus previous studies.^[iii] (https://u7061146.ct.sendgrid.net/=
ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuFBcNiBA2efNfLIHxSZVXCM-3DdWyE_xDPID0v=
OuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52=
Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFq=
jiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1Lge4A8J=
q7kfaQylXnDgAvSDL-2BWsHPrIOKt27kLKtF-2BdfArufm-2FkrLUFxwIoiCp-2BS-2FiQpkwd5=
z2mxDKOFcFPE4rIGK9S2HkCKrc9L9PKByEUl1dznYp2pUS6rGokZI2qZVXSzB3XTccNmW-2FvMe=
qyOp2pU-3D
=C2=A0
=C2=B7 The Phase 2b BE ACTIVE study showed that bimekizumab-treated patient=
s with active PsA achieved rapid clinical improvements in joint and skin ou=
tcomes as well as improvements in patient-reported quality of life (QoL) me=
asures.^[iv] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4=
pR0LkVwhBuMl2pAI8RYqjEa-2BDKWHYIYM-3DlQZd_xDPID0vOuylFAU8fv4e60wei4JxqEGBdV=
Wu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c=
9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf=
-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgbCiCSO8QPsmmo-2B5dyc71qTFQQF8Br=
SJul8YCt707pDUsR9EiDq-2F-2FAZnvCLXHaU4cDzxoj1lV-2BKs8k4QqQJYq4IkklDuao7lKVk=
Wrg4kwZ6JMe6j8cZLMkv0uAmVDW84MmFQYhKN9JOAb6TODSdIWpY-3D Of the patients in =
the bimekizumab dosing groups (160 mg, 160 mg with a 320 mg loading dose, o=
r 320 mg Q4W), 47.5 to 58.5 percent achieved Health Assessment Questionnair=
e Disability Index (HAQ-DI) achieving Minimal Clinically Important Differen=
ce (MCID), and more than 75 percent achieved Psoriatic Arthritis Impact of =
Disease-9 (PsAID-9) Patient Acceptable Symptom State (PASS) across weeks 12=
, 24 and 48, for both measures.^[iv] (https://u7061146.ct.sendgrid.net/ls/c=
lick?upn=3DoAq-2FBqldth4pR0LkVwhBuMl2pAI8RYqjEa-2BDKWHYIYM-3DF5JH_xDPID0vOu=
ylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zl=
f-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqji=
ie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgQl5egJb=
M0m60FfKIE4LE23ICaStq6-2BnGQxdN4BQ7KZH1MFlQua8cuLxYQoUvyuEcI4MqobppNgKpF-2F=
LzYDynsUyEDkZvqVZPR2bZJMGY-2Fddhp5SZ6l-2F66UFJEmUUrzjzDUMYEaU-2F-2FTbPtAMMT=
i4310-3D These results reinforce bimekizumab=E2=80=99s strong potential to =
positively impact QoL for patients with PsA.^[iv] (https://u7061146.ct.send=
grid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuMl2pAI8RYqjEa-2BDKWHYIYM-3Do=
dYL_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqdd=
W-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2B=
dQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq=
2uc1LgTlg3V-2FWp2olu8OavlIGi8ivw13RSfIvz-2BAxJU9kyQ6GWMGLrjKYzAI9kJqnGKGd-2=
FITEUKNsk23SU1CW0W8iXdKFBK2QeEkmkmXDXeS3NeWDTqRkdn7DRMWAiikIlcWqEvIEWrROdoa=
-2BleeMJgnRjRk-3D

=C2=B7 The BE ACTIVE OLE study investigated long-term efficacy and safety o=
f bimekizumab treatment in patients with active PsA over a total treatment =
duration of 2-years exposure.^[v] (https://u7061146.ct.sendgrid.net/ls/clic=
k?upn=3DoAq-2FBqldth4pR0LkVwhBuC5O4f98-2BWjSlNxDjVYDxjI-3D4XeK_xDPID0vOuylF=
AU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2=
FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2=
L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgYszP3wt2mM=
NkO4iguc2eDzAyxNHZLYXdWLESoe6I7dpNYIhzMM25MQ-2F6elquXttLZNRmOUdG5f1qLNhpIg2=
P7kDPBhfMF6YVuPhdZxWQIJZgiLZXBM5hT6x1RAlA8neUlGtro9bdimhNGjqQJoYrOI-3D All =
patients who entered the OLE trial received 160 mg Q4W.^[v] (https://u70611=
46.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuC5O4f98-2BWjSlNxDj=
VYDxjI-3D6Lek_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kxv=
Ps6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebV=
hW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FX=
ANGvQDfUDq2uc1LgeY73cQChRWPX-2F-2FYJFGoICxQc1UWnlJn-2BuLOVQPggs4ekaoiJNeWIj=
1NCUdgAdSw-2BiTd1Zpc6O-2Ft92sBX6FWEaqxn9wDxuEcKfoveLYAq-2BcXBLipbkiNzMX-2B0=
k-2FBVM-2FTypfOf6m7thC0iefpxN8QMC4-3D A high proportion of patients initial=
ly randomized to the three highest bimekizumab doses (160 mg, 160 mg with a=
320 mg loading dose, or 320 mg Q4W) in the BE ACTIVE study and achieved hi=
gh levels of disease control at Week 12 demonstrated maintenance of respons=
es for at least 2 years of therapy across both joint and skin outcomes.^[v]=
(https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuC5=
O4f98-2BWjSlNxDjVYDxjI-3D7q3k_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8=
sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV=
73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93=
v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgVe2T1kfvsxmBeHiahKa8LTw4t3mxDp72-2BO25mBNZT=
-2BNCpmNB4fYrBZ3VKtrRZfc9NVg1RUceElV9OHvUMsRzPWfWoEoIsV5-2BEi4j7dcgr4Ia1dtC=
Xom7u5AHNiLiAw25GqcYHeLqNlx63g7mpLan2g-3D Rates of treatment-emergent adver=
se events (TEAEs) occurred in 87.7 percent of patients and serious TEAEs in=
9.3 percent of patients. The findings suggest bimekizumab maintains a robu=
st treatment response and high level of disease control up to two years.^[v=
] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuC=
5O4f98-2BWjSlNxDjVYDxjI-3DcOQd_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b=
8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWz=
V73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD9=
3v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgbmJmDj0pXW8IZ9lKUSvescudNKNw-2BQmLPk7DMIFr=
h762bSlZ6y-2BE5NdXqVSzrBgbsFaQboLHm-2BIyRKQwbYZvqnyB9h1AiEa0gGTZH-2BBQXCFa-=
2FiCFBDD9GEU69KeM184dW6kguFKiTNA-2FfCzMInmasQ-3D

The safety and efficacy of bimekizumab have not been established and it is =
not approved by any regulatory authority worldwide.

Following is a guide to the UCB-sponsored data presentations:

Bimekizumab e-Posters:

Bimekizumab Long-Term Efficacy and Safety Over 96 Weeks in Patients with An=
kylosing Spondylitis: Interim Results from a Phase 2B Open-Label Extension =
Study
X Baraliakos, A Deodhar, M Dougados, M Oortgiesen, N de Peyrecave, M Bauer,=
T Vaux, C Fleurinck, D van der Heijde

Bimekizumab Treatment is Associated with Improvements in Back Pain and Fati=
gue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Pha=
se 2B Study
A Deodhar, L Gossec, PJ Mease, J Coarse, H Edens, N de Peyrecave, D Assudan=
i, B Ink, CT Ritchlin

Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-W=
eek Results from a Phase 2B Study and Association Between Patient-Reported =
Outcomes and Disease Activity
L Gossec, PJ Mease, AB Gottlieb, D Assudani, J Coarse, B Ink, LC Coates

Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2=
-Year Results from a Phase 2B Dose-Ranging Study and its Open-Label Extensi=
on
JF Merola, F Behrens, AJ Kivitz, PJ Mease, IB McInnes, B Ink, D Assudani, P=
Joshi, J Coarse, CT Ritchlin

CIMZIA e-Posters:

Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyl=
oarthritis Stratified by Baseline MRI and C-Reactive Protein Status
A Deodhar, LS Gensler, S Hall, PC Robinson, B Hoepken, L Bauer, T Kumke, WP=
Maksymowych

Predictors of Response in Patients with Non-Radiographic Axial Spondyloarth=
ritis Receiving Certolizumab Pegol in the C-axSpAnd Study
WP Maksymowych, T Kumke, SE Auteri, B Hoepken, L Bauer, M Rudwaleit

Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthrit=
is During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Stu=
dy
I van der Horst-Bruinsma, RE van Bentum, FD Verbraak, T Rath, JT Rosenbaum,=
B Hoepken, O Irvin-Sellers, T Kumke, L Bauer, M Rudwaleit

Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Mo=
difying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Na=C3=AFve Patients with N=
on-Radiographic Axial Spondyloarthritis
S Kiri, M Kim, M Betts, M Chitnis, K Fahrbach, J Tarpey, M Turner

Achievement of Remission is Associated with Improvement in Functionality in=
Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective=
of Pre-Existing Radiographic Structural Damage
LC Coates, D van der Heijde, LE Kristensen, WR Tillett, J Eells, T Nurminen=
, A Deodhar

About Bimekizumab

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that s=
electively inhibits both IL-17A and IL-17F, two key cytokines driving infla=
mmatory processes.^[vi] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoA=
q-2FBqldth4pR0LkVwhBuAnv0NgTaTQOiGJnaHvEglI-3DiCWI_xDPID0vOuylFAU8fv4e60wei=
4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekoc=
Vj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2B=
qFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgagvCu57AfkqK8VxvDUvN8R=
NQvnE185XfMcDBgdkiTrD-2B5mqWPeqbULKCU8nGQa5aw8mCAXIewHafoLz7s9Y-2FZstHKKMuu=
7lf21MH2lijlsS4niGJCw7rHw-2FK7xy9-2FbKhqf3ru0zlOljAaoumGjr5wc-3D IL-17F has=
overlapping biology with IL-17A and drives inflammation independently to I=
L-17A.^[vii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4=
pR0LkVwhBuFTgNr2ESIHhcZyRQtfLCeQ-3D4v4E_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu=
7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g=
1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2=
Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgTkPDXDelM07vjP1WUfOmIq0UZ-2F0mdT8=
9CO-2B90f-2F1sub5W2eLqEVEFvkUFAt2qf91I5HBoksz7XRot9Ql95vAl7TbtXZ3ilqgSJS7pI=
tpVhONBmQORlIExudkBnX6XkBWsdO3kWP3HQ00T6gk6dzrkA-3D ,[viii] (https://u70611=
46.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuLcPIYk5ZPXgBoACvGk=
xgMo-3DJ325_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs=
6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW=
9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXAN=
GvQDfUDq2uc1LgQs6TRU7Y0OMVcim35R-2BS22JpGSkmisuqHkCE6e-2FKBxG1cvU1-2FpdqPIh=
kC-2FeubmpLSmynAQBV-2Fl4Pj6BLJ2ZxvImpTVYukgSeOKW7YjAvKfTTLjwXSXs1mc1EWml3YF=
DJcG7B7y8-2B83-2Fl5uuF3vm4cc-3D ,[ix] (https://u7061146.ct.sendgrid.net/ls/=
click?upn=3DoAq-2FBqldth4pR0LkVwhBuAW-2FECEiktYFAhNm39VAZCo-3DbMPD_xDPID0vO=
uylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Z=
lf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqj=
iie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgW193QF=
FTZh7dtQBp7Bz-2FiF4CZSfAeEeWiwC9-2F1LC3dYssCudsEvgOqQEg1YvPUdSjj3TAFs5VaR86=
VpeRRwWmlY6kOk89y02TMa0OekLgLQZ72DBKEMpmxVoI8Gik31Fng6ID-2F6gUowgUgohBRQn78=
-3D ,[x] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0L=
kVwhBuAD-2F9Led7NOXiJRBklEPFxc-3DUDGo_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7K=
iDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1w=
ZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Bo=
a2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgUC6LEpp6rCJto0IwGjmWorU0DYRz149955m=
QSbVV-2B030T2IGVTcbGA0rS39PAL5-2BfcgzL4ed6z-2FlfND3WCIZa4V0XpjxIsFBGeuLnSA6=
iADOaL8CNxXpGvNrA0nAD7UeNIeMAvE70fDD13gngtg5q4-3D ,[xi] (https://u7061146.c=
t.sendgrid.net/ls/click?upn=3DoAq-2FBqldth4pR0LkVwhBuC3QqARYenFWib-2FO1bVUF=
ko-3D7xqc_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6E=
FaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9Z=
UHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGv=
QDfUDq2uc1LgZi8h-2Bm55EsxHDXqPtFbToVBCCgeoYHyelS8RbyUOFuOpIrcCfxCzQ3YFNyPVM=
HDeZJOshe650QiBRGtLi4Eb-2BBeROywZ1B-2BZ5ye7Kp012-2ByFM4TZI-2FHCYHQZruWm4C7R=
LjGAVrOcffMeJ8SegTlrg8-3D Selective inhibition of IL-17F in addition to IL-=
17A suppresses inflammation to a greater extent than IL-17A inhibition alon=
e.10^,11 The safety and efficacy of bimekizumab are being evaluated across =
multiple disease states as part of a robust clinical program.

About CIMZIA^=C2=AE=C2=A0in the US

CIMZIA^=C2=AE is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Facto=
r). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizin=
g the pathophysiological effects of TNF-alpha.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD)=
and maintaining clinical response in adult patients with moderately to sev=
erely active disease who have had an inadequate response to conventional th=
erapy.

CIMZIA is also indicated for the treatment of adults with moderately to sev=
erely active rheumatoid arthritis (RA), adults with active psoriatic arthri=
tis (PsA), adults with active ankylosing spondylitis (AS), and adults with =
active non-radiographic axial spondyloarthritis (nr-axSpA) with objective s=
igns of inflammation.

In addition, CIMZIA is indicated for the treatment of moderate to severe pl=
aque psoriasis (PSO) in adults who are candidates for systemic therapy or p=
hototherapy. See important safety information including risk of serious bac=
terial, viral and fungal infections and tuberculosis below.

IMPORTANT SAFETY INFORMATION about CIMZIA in the U.S.

CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity re=
action to certolizumab pegol or to any of the excipients. Reactions have in=
cluded angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious i=
nfections that may lead to hospitalization or death. Most patients who deve=
loped these infections were taking concomitant immunosuppressants such as m=
ethotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

=C2=B7 Active tuberculosis (TB), including reactivation of latent TB. Patie=
nts with TB have frequently presented with disseminated or extrapulmonary d=
isease. Test patients for latent TB before CIMZIA use and during therapy. I=
nitiate treatment for latent TB prior to CIMZIA use.
=C2=B7 Invasive fungal infections, including histoplasmosis, coccidioidomyc=
osis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patien=
ts with histoplasmosis or other invasive fungal infections may present with=
disseminated, rather than localized, disease. Antigen and antibody testing=
for histoplasmosis may be negative in some patients with active infection.=
Consider empiric anti-fungal therapy in patients at risk for invasive fung=
al infections who develop severe systemic illness.
=C2=B7 Bacterial, viral, and other infections due to opportunistic pathogen=
s, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to=
initiating therapy in the following patients: with chronic or recurrent in=
fection;=C2=A0 who have been exposed to TB;=C2=A0 with a history of opportu=
nistic infection; who resided in or traveled in regions where mycoses are e=
ndemic; with underlying conditions that may predispose them to infection. M=
onitor patients closely for the development of signs and symptoms of infect=
ion during and after treatment with CIMZIA, including the possible developm=
ent of TB in patients who tested negative for latent TB infection prior to =
initiating therapy.

=C2=B7 Do not start CIMZIA during an active infection, including localized =
infections.
=C2=B7 Patients older than 65 years, patients with co-morbid conditions, an=
d/or patients taking concomitant immunosuppressants may be at greater risk =
of infection.
=C2=B7 If an infection develops, monitor carefully and initiate appropriate=
therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children=
and adolescent patients treated with TNF blockers, of which CIMZIA is a me=
mber. CIMZIA is not indicated for use in pediatric patients.

=C2=B7 Consider the risks and benefits of CIMZIA treatment prior to initiat=
ing or continuing therapy in a patient with known malignancy.
=C2=B7 In clinical trials, more cases of malignancies were observed among C=
IMZIA-treated patients compared to control patients.
=C2=B7 In CIMZIA clinical trials, there was an approximately 2-fold higher =
rate of lymphoma than expected in the general U.S. population. Patients wit=
h rheumatoid arthritis, particularly those with highly active disease, are =
at a higher risk of lymphoma than the general population.
=C2=B7 Malignancies, some fatal, have been reported among children, adolesc=
ents, and young adults being treated with TNF blockers.=C2=A0Approximately =
half of the cases were lymphoma, while the rest were other types of maligna=
ncies, including rare types associated with immunosuppression and malignanc=
ies not usually seen in this patient population.
=C2=B7 Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare=
type of T-cell lymphoma, have been reported in patients treated with TNF b=
lockers, including CIMZIA. These cases have had a very aggressive disease c=
ourse and have been fatal. The majority of reported TNF blocker cases have =
occurred in patients with Crohn=E2=80=99s disease or ulcerative colitis, an=
d the majority were in adolescent and young adult males.=C2=A0 Almost all o=
f these patients had received treatment with azathioprine or 6-mercaptopuri=
ne concomitantly with a TNF blocker at or prior to diagnosis. Carefully ass=
ess the risks and benefits of treating with CIMZIA in these patient types.
=C2=B7 Cases of acute and chronic leukemia were reported with TNF blocker u=
se.

HEART FAILURE

=C2=B7 Worsening and new onset congestive heart failure (CHF) has been repo=
rted with TNF blockers. Exercise caution and monitor carefully.

HYPERSENSITIVITY

=C2=B7 Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness,=
and urticaria have been reported following CIMZIA administration. If a ser=
ious allergic reaction occurs, stop CIMZIA and institute appropriate therap=
y. The needle shield inside the removable cap of the CIMZIA prefilled syrin=
ge contains a plastic derivative of natural rubber latex which may cause an=
allergic reaction in individuals sensitive to latex.

HEPATITIS B VIRUS REACTIVATION

=C2=B7 Use of TNF blockers, including CIMZIA, may increase the risk of reac=
tivation of hepatitis B virus (HBV) in patients who are chronic carriers. S=
ome cases have been fatal.
=C2=B7 Test patients for HBV infection before initiating treatment with CIM=
ZIA.
=C2=B7 Exercise caution in patients who are carriers of HBV and monitor the=
m before and during CIMZIA treatment.
=C2=B7 Discontinue CIMZIA and begin antiviral therapy in patients who devel=
op HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatm=
ent.

NEUROLOGIC REACTIONS

=C2=B7 TNF blockers, including CIMZIA, have been associated with rare cases=
of new onset or exacerbation of central nervous system and peripheral demy=
elinating diseases, including multiple sclerosis, seizure disorder, optic n=
euritis, peripheral neuropathy, and Guillain-Barr=C3=A9 syndrome.

HEMATOLOGIC REACTIONS

=C2=B7 Rare reports of pancytopenia, including aplastic anemia, have been r=
eported with TNF blockers. Medically significant cytopenia has been infrequ=
ently reported with CIMZIA.
=C2=B7 Consider stopping CIMZIA if significant hematologic abnormalities oc=
cur.

DRUG INTERACTIONS

=C2=B7 Do not use CIMZIA in combination with other biological DMARDS.

AUTOIMMUNITY

=C2=B7 Treatment with CIMZIA may result in the formation of autoantibodies =
and, rarely, in development of a lupus-like syndrome. Discontinue treatment=
if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

=C2=B7 Patients on CIMZIA should not receive live or live-attenuated vaccin=
es.

ADVERSE REACTIONS

=C2=B7 The most common adverse reactions in CIMZIA clinical trials (=E2=89=
=A58%) were: upper respiratory infections (18%), rash (9%), and urinary tra=
ct infections (8%).

For full prescribing information, please visit

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdKdn=
kD23fns-2FvC-2FH2O-2FRu906jSnkSmAsA6kkfIJiZLZFYPecTEBc0DLeE4Es5opQAqUaLqtEK=
-2BdxgvhbitwZiSbXHp-2BKk1OjR8zGw0xJqLE9D4-_xDPID0vOuylFAU8fv4e60wei4JxqEGBd=
VWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9=
c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqD=
f-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1Lga4DmC-2BNfVzH3d1-2FCnEyhbTZnxa=
WFbtQqPXKyxmq2QVKpX6-2BePbbIAp6dVjn-2BnLK9Tjx2fiJQAOCh1EcSDc9V-2B0U-2FhlGEM=
GZnH8AWXfpaV8p-2Fb7Xz9ISkM2u-2FIGtrJz-2F-2BnV90hhwflidEWem6JRMAuU-3D

About CIMZIA^=C2=AE=C2=A0in the EU/EEA
In the EU, CIMZIA^=C2=AE=C2=A0in combination with methotrexate (MTX) is ind=
icated for the treatment of moderate to severe active RA in adult patients =
inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) =
including MTX.=C2=A0

CIMZIA can be given as monotherapy in case of intolerance to MTX or when co=
ntinued treatment with MTX is inappropriate. CIMZIA in combination with MTX=
is also indicated for the treatment of severe, active and progressive RA i=
n adults not previously treated with MTX or other DMARDs.

CIMZIA has been shown to reduce the rate of progression of joint damage as =
measured by X-ray and to improve physical function, when given in combinati=
on with MTX.

CIMZIA, in combination with MTX, is also indicated for the treatment of act=
ive psoriatic arthritis in adults when the response to previous DMARD thera=
py has been inadequate. CIMZIA can be given as monotherapy in case of intol=
erance to MTX or when continued treatment with MTX is inappropriate.

CIMZIA is also indicated in the EU for the treatment of adult patients with=
severe active axial spondyloarthritis (axSpA), comprising:=C2=A0

=C2=B7 Ankylosing spondylitis (AS) =E2=80=93 adults with severe active AS w=
ho have had an inadequate response to, or are intolerant to non-steroidal a=
nti-inflammatory drugs (NSAIDs).=C2=A0
=C2=B7 Axial spondyloarthritis (axSpA) without radiographic evidence of AS =
=E2=80=93 adults with severe active axSpA without radiographic evidence of =
AS but with objective signs of inflammation by elevated C-reactive protein =
(CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate re=
sponse to, or are intolerant to NSAIDs.

CIMZIA is also indicated for the treatment of moderate to severe plaque pso=
riasis in adults who are candidates for systemic therapy.=C2=A0

Cimzia^=C2=AE (certolizumab pegol) EU/EEA* Important Safety Information

Cimzia^=C2=AE was studied in 4,049 patients with rheumatoid arthritis (RA) =
in controlled and open label trials for up to 92 months. The commonly repor=
ted adverse reactions (1-10 percent) in clinical trials with Cimzia^=C2=AE =
and post-marketing were viral infections (includes herpes zoster, papilloma=
virus, influenza), bacterial infections (including abscess), rash, headache=
(including migraine), asthenia, leukopenia (including lymphopenia, neutrop=
enia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalit=
ies, hypertension, pruritus (any sites), hepatitis (including hepatic enzym=
e increase), injection site reactions, and nausea. Serious adverse reaction=
s include sepsis, opportunistic infections, tuberculosis (including miliary=
, disseminated and extrapulmonary), herpes zoster, lymphoma, leukaemia, sol=
id organ tumours, angioneurotic oedema, cardiomyopathies (includes heart fa=
ilure), ischemic coronary artery disorders, pancytopenia, hypercoagulation =
(including thrombophlebitis, pulmonary embolism), cerebrovascular accident,=
vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairme=
nt/nephropathy (includes nephritis). In RA controlled clinical trials, 4.4 =
percent of patients discontinued taking Cimzia^=C2=AE due to adverse events=
vs. 2.7 percent for placebo.

Cimzia^=C2=AE was initially studied in 325 patients with active axial spond=
yloarthritis (including ankylosing spondylitis and non-radiographic axial s=
pondyloarthritis) in the AS001 clinical study for up to 4 years, which incl=
udes a 24-week placebo-controlled phase followed by a 24-week dose-blind pe=
riod and a 156-week open-label treatment period. Cimzia^=C2=AE was subseque=
ntly studied in 317 patients with non-radiographic axial spondyloarthritis =
in a placebo-controlled study for 52 weeks (AS0006). Cimzia^=C2=AE was also=
studied in patients with axial spondyloarthritis (including ankylosing spo=
ndylitis and non-radiographic axial spondyloarthritis) in a clinical study =
for up to 96 weeks, which included a 48-week open-label run-in phase (N=3D7=
36) followed by a 48-week placebo-controlled phase (N=3D313) for patients i=
n sustained remission (C-OPTIMISE). In all 3 studies, the safety profile fo=
r these patients was consistent with the safety profile in rheumatoid arthr=
itis and previous experience with Cimzia^=C2=AE.=C2=A0

Cimzia^=C2=AE was studied in 409 patients with psoriatic arthritis (PsA) in=
a clinical study for up to 4 years which included a 24-week placebo-contro=
lled phase followed by a 24-week dose-blind period and a 168-week open-labe=
l treatment period.

The safety profile for axSpA and PsA patients treated with Cimzia^=C2=AE wa=
s consistent with the safety profile in RA and previous experience with Cim=
zia^=C2=AE.

Cimzia^=C2=AE was studied in 1112 patients with psoriasis in controlled and=
open-label studies for up to 3 years. In the Phase III program, the initia=
l and maintenance periods were followed by a 96-week open-label treatment p=
eriod. The long-term safety profile of Cimzia^=C2=AE 400 mg every 2 weeks a=
nd Cimzia^=C2=AE 200 mg every 2 weeks was generally similar and consistent =
with previous experience with Cimzia.

Cimzia^=C2=AE is contraindicated in patients with hypersensitivity to the a=
ctive substance or any of the excipients, active tuberculosis or other seve=
re infections such as sepsis or opportunistic infections, and moderate to s=
evere heart failure.

Serious infections including sepsis, tuberculosis and opportunistic infecti=
ons (e.g. histoplasmosis, nocardia, candidiasis) have been reported in pati=
ents receiving Cimzia^=C2=AE. Some of these events have been fatal. Before =
initiation of therapy with Cimzia^=C2=AE, all patients must be evaluated fo=
r both active and inactive (latent) tuberculosis infection. If active tuber=
culosis is diagnosed prior to or during treatment, Cimzia^=C2=AE therapy mu=
st not be initiated and must be discontinued. If latent tuberculosis is dia=
gnosed, appropriate anti-tuberculosis therapy must be started before initia=
ting treatment with Cimzia^=C2=AE.

Reactivation of hepatitis B has occurred in patients receiving a TNF-antago=
nist including Cimzia^=C2=AE who are chronic carriers of the virus (i.e. su=
rface antigen positive). Some cases have had a fatal outcome. Patients shou=
ld be tested for HBV infection before initiating treatment with Cimzia^=C2=
=AE. Carriers of HBV who require treatment with Cimzia^=C2=AE should be clo=
sely monitored and in the case of HBV reactivation Cimzia^=C2=AE should be =
stopped and effective anti-viral therapy with appropriate supportive treatm=
ent should be initiated.

TNF antagonists including Cimzia^=C2=AE may increase the risk of new onset =
or exacerbation of clinical symptoms and/or radiographic evidence of demyel=
inating disease including multiple sclerosis; of formation of autoantibodie=
s and uncommonly of the development of a lupus-like syndrome; of severe hyp=
ersensitivity reactions. If a patient develops any of these adverse reactio=
ns, Cimzia^=C2=AE should be discontinued and appropriate therapy instituted.

With the current knowledge, a possible risk for the development of lymphoma=
s, leukaemia or other malignancies in patients treated with a TNF antagonis=
t cannot be excluded. Rare cases of neurological disorders, including seizu=
re disorder, neuritis and peripheral neuropathy, have been reported in pati=
ents treated with Cimzia^=C2=AE.

Adverse reactions of the haematologic system, including medically significa=
nt cytopenia, have been reported with Cimzia^=C2=AE. Advise all patients to=
seek immediate medical attention if they develop signs and symptoms sugges=
tive of blood dyscrasias or infection (e.g., persistent fever, bruising, bl=
eeding, pallor) while on Cimzia^=C2=AE. Consider discontinuation of Cimzia^=
=C2=AE therapy in patients with confirmed significant haematological abnorm=
alities.

The use of Cimzia^=C2=AE in combination with anakinra or abatacept is not r=
ecommended due to a potential increased risk of serious infections. As no d=
ata are available, Cimzia^=C2=AE should not be administered concurrently wi=
th live vaccines. The 14-day half-life of Cimzia^=C2=AEshould be taken into=
consideration if a surgical procedure is planned. A patient who requires s=
urgery while on Cimzia^=C2=AE should be closely monitored for infections.

Please consult the full prescribing information in relation to other side e=
ffects, full safety and

prescribing information.

European SmPC date of revision July 2020.

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdN3E=
U-2FWvZebf3RrOmE3Tk7MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH9nu7OTyWvLsHd=
N1-2FyZYmHi9NLhb7vDDKsRPZltwUi15U5BPBnLh0FBflBDzTkqACQ-3D-3DgNFx_xDPID0vOuy=
lFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf=
-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjii=
e2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgbqTkkxw0=
gVLB1whBeLL5NWH2keGp-2B2Df5a2Cm5DRFgIhOhw6yRFm8-2FccOsz6QN34qVMrJs15T-2FYc1=
CSHxBHqXYxCDrk1Fq4EKNhJedBu6dUpC2aKbfYqgcmnnbRJw-2BknmmbUOVvkYYHYnSmM3cwAZI=
-3D

CIMZIA^=C2=AE=C2=A0is a registered trademark of the UCB Group of Companies.

[i] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647-2=
FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wrmhAt8M2Kh=
Ma7A5hYossEA-3DkHLo_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86b=
Sl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1rt=
tkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z=
4U80FXANGvQDfUDq2uc1LgWHvIvEq0yWcCzWLF1AYlCxgLfe82Ac47jqLkT6O26T-2By6efzafL=
iTmYbb9tTXoawDE9Wqz5Oa-2B3BugJslJ28l4wjzC-2FK-2FJ9qTu8V72F-2BbmGVkXmsVdNAUL=
dvZf8BXE1OJJDFPcHcb3JtAXF5PEghHc-3D van der Horst-Bruinsma I, van Bentum RE=
, Verbraak FD, et al. Reduction of anterior uveitis flares in patients with=
axial spondyloarthritis during certolizumab pegol treatment: 96-week resul=
ts from the c-view study. Abstract to be presented at ACR 2020, 5-9 Novembe=
r.

[ii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647-=
2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wizlFR7zUi=
XQgPJJrEATglQ-3D0tkR_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86=
bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1r=
ttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8=
z4U80FXANGvQDfUDq2uc1LgUdzoRGMv3N-2F90zAhLXzzpsrPIa-2B8aXr-2FbOM9HAT0TQEkh3=
aLp8IxsCtVbBrHJlPDrghZNWK4MS7We6-2FFPoc8YegiUfITP-2FZJX9OJ5dMKPIgoZq-2FZjcU=
5R-2FJVAPH7b-2BAYowBjnQgSB3gaJ9J9SHVYRI-3D Deodhar A, LS Gensler, Hall S, e=
t al. Certolizumab pegol efficacy in patients with nonradiographic axial sp=
ondyloarthritis stratified by baseline mri and creactive protein status. Ab=
stract to be presented at ACR 2020, 5-9 November.

[iii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647=
-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wll6rtIsL=
EnLdDjAKMa6COI-3DvGeS_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL8=
6bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1=
rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq=
8z4U80FXANGvQDfUDq2uc1LgZu0s8osO8qkj3itQ-2BIl8PYll5fiBRqCjxT3IZ5uydnBV3WDsh=
IWU-2ByveUQJ3OUe-2BbDISsv-2FWeFr-2BYAhrOMXOrijZIfA24sfEgaDfhomU2lanuTXEuJ0P=
bKlqj6p3tJ2XdrbJ-2BwkffyvJujkVj2XjWk-3D Baraliakos X, Deodhar A, Dougados M=
, et al. Bimekizumab long-term efficacy and safety over 96 weeks in patient=
s with ankylosing spondylitis: interim results from a phase 2b open-label e=
xtension study. Abstract to be presented at ACR 2020, 5-9 November.

[iv] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647-=
2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wnPevxnjHx=
BkRNrrZx0S5KE-3DZXgE_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86=
bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1r=
ttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8=
z4U80FXANGvQDfUDq2uc1Lgeg3D5y70Ck3PrT0hoyq4BuZZ8O9gll-2FG-2BQV6qIlaTfIyFnTb=
dDwRsMsk89DJvOym7fTbguUGzR4X-2BZ9vNgdOPhLW-2F11K7g1n5Z1dqpuwIbAWLbu53UxXsbX=
xgd47193v2TkY5CEq88M-2F6x-2B1WH6FhE-3D Gossec L, Mease PJ, Gottlieb AB, et =
al. Bimekizumab improves patient-reported outcomes in psoriatic 2 arthritis=
: 48-week results from a phase 2b study and association 3 between patient-r=
eported outcomes and disease activity. Abstract to be presented at ACR 2020=
, 5-9 November.

[v] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647-2=
FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wqGtalAyvKl=
KS8OS6CoQ-2B-2FE-3DFxyr_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46D=
L86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqty=
y1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZe=
Xq8z4U80FXANGvQDfUDq2uc1Lgd4LfSGiuPjOK5zE-2B8IkPru37di48KDIXPZpwSEOt3s6-2FT=
dvHNxhGMy9x5ioiJzdrVgCTgAvcdFwI-2BswYgqlbcwk1pJ5DJwK5xTYTrUrMgRTw638oBrxI23=
H4p7nP1lfxbEieVTY-2FWieIplkc1DMRH8-3D Merola JF, Behrens F, Kivitz AJ, et a=
l. Bimekizumab maintenance of response in patients with psoriatic arthritis=
: 2 year results from a phase 2b dose ranging study and its open label exte=
nsion. Abstract to be presented at ACR 2020, 5-9 November.

^^[vi] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St64=
7-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wlG0KBW4=
cuH7AizLmKKol4Q-3DZTpn_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL=
86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy=
1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeX=
q8z4U80FXANGvQDfUDq2uc1LgQ8fhfEKWEtD3ruz-2FccWoeCbCZvyo8cqdL8QNYUwOWzQ0glQu=
D2DRfoefgIVDkho0UVN1CBoQlA28NXPKBRvnvUp8DjjlHWKv-2BcoI-2Bm8jbyDHFjpZtOcN3wP=
YKa7qtkOMQ5bhKPeTNtUAfYCi-2FCRtVs-3D Glatt S, Helmer E, Haier B, et al. Fir=
st-in-human randomized study of bimekizumab, a humanized monoclonal antibod=
y and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br =
J Clin Pharmacol. 2017;83(5):991-1001.

^^[vii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St6=
47-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wqy-2FD=
PGVtWXt2q98vyDjiTw-3D1EQd_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN4=
6DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pq=
tyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZW=
ZeXq8z4U80FXANGvQDfUDq2uc1LgeJf6uvd4Hi2jC-2BlAcmAWVE2a5gb-2FWuJL5Ai9kN9UMFm=
fl25u7Gf7eH-2F6kiQ1Npqp8Sm-2B0NtbvSPpZVpyi8DhGx5FwUBs4CHl2MCog-2FqhAhBk0yJP=
IavJ8zaZA1NT7rdaqLpG7ug1iaw5lovoCw-2FzPs-3D ^ Yang XO, Chang SH, Park H, et=
al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5)=
:1063=E2=80=931075.

^^[viii] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St=
647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wpjLwP=
PoOF6BDtyzyhlM0uo-3D9UuO_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46=
DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqt=
yy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZ=
eXq8z4U80FXANGvQDfUDq2uc1LgRQTTn8lQ2heSRLMdOYMOJm67uGhz2eVnxXSvJbGlkveWqyXd=
csDGSXnV7EV-2FtG9AVAh-2BDpPyK-2FeqEwQN9Pj-2FsQ6UFJLpV0ii3SrbZlL4cGBUtDn0zsm=
QkhC-2FufrDCXeVw7qqfAv92Pz-2Fl2b5M7uaCo-3D Hymowitz SG, Filvaroff EH, Yin J=
P, et al. IL-17s adopt a cystine knot fold: structure and activity of a nov=
el cytokine, IL-17F, and implications for receptor binding. Embo J. 2001;20=
(19):5332=E2=80=935341.

^^[ix] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St64=
7-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wjEb3txI=
DqwgBsM9b2NOFw0-3D-zH4_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL=
86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy=
1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeX=
q8z4U80FXANGvQDfUDq2uc1LgRCFqgxwnkrx-2BkCq8mGM6C4lwcIajB9wsWbbG3BQQ65HRyLHQ=
bMFGLtw-2BhmLdddE2NvmuMgPCpCtZkdQ-2F1BwsWNRHctryH0PsJO2qiMQdUWL3er3BBq-2FSk=
EcqrggOULyiIlC2G4fHKxnbD1OooZGV5A-3D van Baarsen LG, Lebre MC, van der Coel=
en D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), =
IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic a=
rthritis and osteoarthritis: possible explanation for nonresponse to anti-I=
L-17 therapy? Arthritis Res Ther. 2014;16(4):426.

^^[x] (https://u7061146.ct.sendgrid.net/ls/click?upn=3DvgPU0L08DtdYS96St647=
-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8Vbc5rd23Nd5xqiCbohR6wqMcnjc89=
-2BpUh0tDE0wAXpk-3Dkhmu_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46D=
L86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqty=
y1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZe=
Xq8z4U80FXANGvQDfUDq2uc1LgWR81NHjJjyH52NYtSA8GPLd5snWidYjzusQslO1Flbt2efpEt=
PA3LnFB80c7-2BUVPiVLsyzI6fOu2XqwXNGqwT4v1kR9S3-2FNyrrse1sY2-2B7gvQZ-2BnwKXl=
B4PCyzWH9J-2FdPFx7jyVaONnsvP2P-2FTZKGY-3D ^ Maroof A, Okoye R, Smallie T, e=
t al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of=
IL-17F contribution to chronic inflammation in disease-relevant cells. Ann=
Rheum Dis. 2017;76(2):213.^^[xi] (https://u7061146.ct.sendgrid.net/ls/clic=
k?upn=3DvgPU0L08DtdYS96St647-2FWTri9gpFTm0xN6MV3nJXOmyXtVYPGXbkMyJHlOgqDj8V=
bc5rd23Nd5xqiCbohR6wonKcbUhJWAB-2Badjit7S4hE-3D6spE_xDPID0vOuylFAU8fv4e60we=
i4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9eko=
cVj-2F2X9c9g1wZxSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2=
BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgezLBDgCC4e-2BS7gsWoR3=
rAGlT1V-2BfC22NifBjBHaii9WAfHxPDeEik8yO7uy64JUZ4Ii1ijHOSaZyJ5YI-2BBqrXLkdF3=
vUueiRJaUk-2Fym-2BLDGjEISzCUTCA3EnWwTUbg8zlaENKK-2BucRMguWB-2BryamR0-3D ^ G=
latt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by =
bimekizumab in psoriatic arthritis: evidence from preclinical experiments a=
nd a randomised placebo-controlled clinical trial that IL-17F contributes t=
o human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532.

For further information, UCB:

Corporate Communications
Laurent Schots,
Media Relations, UCB
T+32.2.559.92.64
laurent.schots@ucb.com

Investor Relations
Antje Witte,=C2=A0=C2=A0 =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
Investor Relations, UCB
T +32.2.559.94.14
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588
isabelle.ghellynck@ucb.com

Brand Communications
Andrea Christopher,
Immunology Communications, UCB=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
T +1.404.483.7329
andrea.christopher@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 600 people in=
approximately 40 countries, the company generated revenue of =E2=82=AC 4.9=
billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow =
us on Twitter: @UCB_news.

Forward looking statements UCB

This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products which are the subject of partnersh=
ips, joint ventures or licensing collaborations may be subject to differenc=
es disputes between the partners or may prove to be not as safe, effective =
or commercially successful as UCB may have believed at the start of such pa=
rtnership. UCB=E2=80=99 efforts to acquire other products or companies and =
to integrate the operations of such acquired companies may not be as succes=
sful as UCB may have believed at the moment of acquisition. Also, UCB or ot=
hers could discover safety, side effects or manufacturing problems with its=
products and/or devices after they are marketed. The discovery of signific=
ant problems with a product similar to one of UCB=E2=80=99s products that i=
mplicate an entire class of products may have a material adverse effect on =
sales of the entire class of affected products. Moreover, sales may be impa=
cted by international and domestic trends toward managed care and health ca=
re cost containment, including pricing pressure, political and public scrut=
iny, customer and prescriber patterns or practices, and the reimbursement p=
olicies imposed by third-party payers as well as legislation affecting biop=
harmaceutical pricing and reimbursement activities and outcomes. Finally, a=
breakdown, cyberattack or information security breach could compromise the=
confidentiality, integrity and availability of UCB=E2=80=99s data and syst=
ems.

Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.

UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations. Additionally, inform=
ation contained in this document shall not constitute an offer to sell or t=
he solicitation of an offer to buy any securities, nor shall there be any o=
ffer, solicitation or sale of securities in any jurisdiction in which such =
offer, solicitation or sale would be unlawful prior to the registration or =
qualification under the securities laws of such jurisdiction.

GenericFile
ACR 2020 Data Highlights Press Release (https://u7061146.ct.sendgrid.net/ls=
/click?upn=3D4tNED-2FM8iDZJQyQ53jATUf69zsppm9KssuIC9gumXJeajgJl8MtkU1CFgesz=
I5Bzti0ppnDV9jMnyvXm4vH42g-3D-3DdIsP_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7Ki=
DwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZ=
xSsFWzV73pqtyy1rttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa=
2s9SD93v6ZWZeXq8z4U80FXANGvQDfUDq2uc1LgXgggMFMbSgW4TneueW4qkw6f2ZKva0rONNSW=
fP1WlQNRprMs8jCB1EjxJ5Ayhqwdfci-2FeOO6Gmm38-2FyiTBfur5VcP-2FWcSX2SEa6rnZ2y4=
AA2P8sfvX-2F5OYSp4d-2B6jsraXRwYo2U8iOeKWpQAQlTbw0-3D=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXBhm6lGWHhVShJ-2FxtfBR3KWIv0jCv8=
kMDRJANBNcwGQI6o1ipGMNGzP4nq6hXUR9-2FNZuB3Kge-2FwbPCP5cSX-2B5aQ-2BR8pYiTglx=
4OS6-2B9CRHjw-3D9Z-m_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86=
bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZxSsFWzV73pqtyy1r=
ttkKebVhW9ZUHl-2BdQkIyimWUFqjiie2L16V7M-2B-2BqFY9cqqDf-2Boa2s9SD93v6ZWZeXq8=
z4U80FXANGvQDfUDq2uc1LgYMC7KUD-2FoLOBGVrwgkHxdAS3WE3HCmHHV0yH5sukaiLijcnt0f=
D-2F-2FOK4DKWGFu9w-2F5KZDYNxghph2N2e5GtBBhM5mwf7fUKDpaCeduFusxdDoGV4PR9gmDW=
AsJwydl1Ue4Khm-2FdthO1G6N1dcB1Ias-3D=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=